The Scientist

Understanding the Drug Development Process

This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...
Nature

Preclinical pitfalls: How to avoid costly formulation failures

Drug development is an unforgiving business. Discovering a novel molecule is difficult enough, but then it can take years of preclinical studies and molecular tweaking to mitigate a drug’s toxicity, ...
Nature

Machine learning in preclinical drug discovery

Drug-discovery and drug-development endeavors are laborious, costly and time consuming. These programs can take upward of 12 years and cost US $2.5 billion, with a failure rate of more than 90%.
News Medical

Dive into the reasons behind preclinical cancer models failure

The failure rate of novel cancer medicines remains exceptionally high, with around 95% of compounds tested in clinical trials never becoming a medicine, despite all seeming promising in the discovery ...
News Medical

Building Bridges to Scalable Allogeneic Cell Therapy

Ahead of his talk at the 7th Annual Allogeneic Cell Therapies Summit, Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and large-scale ...

Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology

VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the initiation of ...
KXAN

InVivo Biosystems Announces Groundbreaking Innovation in Preclinical Development

EUGENE, OREGON, UNITES STATES OF AMERICA, August 13, 2024 /EINPresswire.com/ -- InVivo Biosystems, a trailblazer in the biotechnology industry, has unveiled ...
Nasdaq

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, announced today ...

Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development

Intravacc offers state-of-the-art analytical methods for identity, content, purity, structure, formulation, stability, and preclinical ...

UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine

Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology ReMDO The ...
Seeking Alpha

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study ...